EA201690513A1 - Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний - Google Patents

Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний

Info

Publication number
EA201690513A1
EA201690513A1 EA201690513A EA201690513A EA201690513A1 EA 201690513 A1 EA201690513 A1 EA 201690513A1 EA 201690513 A EA201690513 A EA 201690513A EA 201690513 A EA201690513 A EA 201690513A EA 201690513 A1 EA201690513 A1 EA 201690513A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
treatment
combination
hyperproliferative diseases
erk
Prior art date
Application number
EA201690513A
Other languages
English (en)
Other versions
EA034872B1 (ru
Inventor
Марсия Белвин
Джон Моффэт
Марк Мёрчант
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA201690513A1 publication Critical patent/EA201690513A1/ru
Publication of EA034872B1 publication Critical patent/EA034872B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Согласно изобретению предложены комбинации, содержащие ингибитор MEK (такой как GDC-0973 или GDC-0623) или его фармацевтически приемлемую соль и ингибитор ERK (такой как GDC-0994). Данные комбинации являются особенно полезными для лечения гиперпролиферативных расстройств, таких как рак.
EA201690513A 2013-09-05 2014-09-04 Комбинация ингибитора mek кобиметиниба и ингибитора erk (s)-1-(1-(4-хлор-3-фторфенил)-2-гидроксиэтил)-4-(2-((1-метил-1h-пиразол-5-ил)амино)пиримидин-4-ил)пиридин-2(1h)-она для применения в лечении раковых заболеваний EA034872B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874206P 2013-09-05 2013-09-05
PCT/EP2014/068776 WO2015032840A1 (en) 2013-09-05 2014-09-04 Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases

Publications (2)

Publication Number Publication Date
EA201690513A1 true EA201690513A1 (ru) 2016-07-29
EA034872B1 EA034872B1 (ru) 2020-03-31

Family

ID=51492945

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690513A EA034872B1 (ru) 2013-09-05 2014-09-04 Комбинация ингибитора mek кобиметиниба и ингибитора erk (s)-1-(1-(4-хлор-3-фторфенил)-2-гидроксиэтил)-4-(2-((1-метил-1h-пиразол-5-ил)амино)пиримидин-4-ил)пиридин-2(1h)-она для применения в лечении раковых заболеваний

Country Status (21)

Country Link
US (1) US9532987B2 (ru)
EP (1) EP3041471A1 (ru)
JP (2) JP2016531139A (ru)
KR (1) KR20160048807A (ru)
CN (1) CN105517548B (ru)
AR (1) AR097556A1 (ru)
AU (1) AU2014317119B2 (ru)
CA (1) CA2916619A1 (ru)
CL (1) CL2016000042A1 (ru)
EA (1) EA034872B1 (ru)
HK (1) HK1218072A1 (ru)
IL (1) IL243251B (ru)
MA (1) MA38827A1 (ru)
MX (1) MX370417B (ru)
PE (1) PE20160529A1 (ru)
PH (1) PH12016500270A1 (ru)
SG (1) SG11201600989VA (ru)
TW (1) TW201605477A (ru)
UA (1) UA120423C2 (ru)
WO (1) WO2015032840A1 (ru)
ZA (1) ZA201600091B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820009T3 (en) * 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
JP6642942B2 (ja) * 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
WO2016162325A1 (en) 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
WO2017080980A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
LT3374359T (lt) 2015-11-09 2020-03-25 Astrazeneca Ab Dihidroimidazopirazinono deriniai, tinkami panaudoti vėžio gydymui
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
AU2017316618A1 (en) 2016-08-23 2019-02-07 Genentech, Inc. Combination therapy for the treatment of pancreatic cancer
DK3425390T3 (da) * 2016-11-25 2021-02-15 Genuv Inc Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
JP2019019094A (ja) * 2017-07-19 2019-02-07 学校法人福岡大学 変異ｋｒａｓ関連シグナル阻害用組成物
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US12377063B2 (en) * 2019-07-11 2025-08-05 Emory University Combination therapies for managing cancer
KR102695469B1 (ko) * 2021-07-23 2024-08-14 차의과학대학교 산학협력단 2,4-디아미노피리미딘을 포함하는 암의 예방 또는 치료용 조성물
CN118001281B (zh) * 2023-12-11 2025-10-17 中国科学院深圳先进技术研究院 一种治疗或预防甲基苯丙胺成瘾的药物及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
AU2007286808B2 (en) 2006-08-21 2012-12-06 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
PE20081354A1 (es) 2006-11-30 2008-11-14 Genentech Inc Compuestos de azaindolilo como inhibidores de mek
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
JP5580735B2 (ja) 2007-06-12 2014-08-27 ジェネンテック， インコーポレイテッド Ｎ−置換アザインドール類及び使用方法
US8293763B2 (en) 2007-12-19 2012-10-23 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
JP5421925B2 (ja) * 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド ５−アニリノイミダゾピリジン及び使用の方法
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
ES2426096T3 (es) 2008-07-01 2013-10-21 Genentech, Inc. Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
US20120214828A1 (en) 2009-08-24 2012-08-23 Georgia Hatzivassiliou Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
CA2776944A1 (en) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
EP2681215B1 (en) 2011-02-28 2015-04-22 Array Biopharma, Inc. Serine/threonine kinase inhibitors
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2014014308A (es) 2012-05-30 2015-02-12 Hoffmann La Roche Pirrolidino heterociclos.
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
TW201408658A (zh) 2012-08-27 2014-03-01 Array Biopharma Inc 絲胺酸／酥胺酸激酶抑制劑
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
JP6642942B2 (ja) 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
BR112016015235A2 (pt) 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
EP3129025B1 (en) 2014-04-09 2019-05-15 Genentech, Inc. Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
AU2014317119A1 (en) 2016-03-03
KR20160048807A (ko) 2016-05-04
PH12016500270A1 (en) 2016-05-16
SG11201600989VA (en) 2016-03-30
JP2016531139A (ja) 2016-10-06
ZA201600091B (en) 2017-04-26
EP3041471A1 (en) 2016-07-13
MX370417B (es) 2019-12-10
US9532987B2 (en) 2017-01-03
EA034872B1 (ru) 2020-03-31
CN105517548A (zh) 2016-04-20
WO2015032840A1 (en) 2015-03-12
CN105517548B (zh) 2020-01-21
IL243251B (en) 2019-02-28
CL2016000042A1 (es) 2016-08-05
TW201605477A (zh) 2016-02-16
MX2016002857A (es) 2016-06-22
US20150111869A1 (en) 2015-04-23
JP2019031517A (ja) 2019-02-28
CA2916619A1 (en) 2015-03-12
AR097556A1 (es) 2016-03-23
AU2014317119B2 (en) 2019-12-05
UA120423C2 (uk) 2019-12-10
PE20160529A1 (es) 2016-05-21
HK1218072A1 (zh) 2017-02-03
MA38827A1 (fr) 2017-10-31

Similar Documents

Publication Publication Date Title
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
IL256166B (en) Compounds for use in treating neuromuscular disorders
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201591509A1 (ru) Ингибиторы cdc7
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX378273B (es) Compuestos activos hacia bromodominios.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MX381640B (es) Metodos y compuestos agonistas de gip.
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201590997A1 (ru) Соединения и способы их применения
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
UA114417C2 (uk) Інгібітори iap
LT3592355T (lt) Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
EA201691130A1 (ru) Средства и способы противодействия миелопролиферативным или лимфопролиферативным расстройствам
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU